• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Smith & Wesson Brands Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket

    9/8/23 8:28:35 AM ET
    $AGBA
    $ASPS
    $BGLC
    $BIOL
    Investment Managers
    Finance
    Other Consumer Services
    Consumer Discretionary
    Get the next $AGBA alert in real time by email

    Gainers

    • Impel Pharmaceuticals Inc. (NASDAQ:IMPL) rose 41.3% to $0.54 in pre-market trading after falling 4% on Thursday.
    • AGBA Group Holding Limited (NASDAQ:AGBA) shares rose 32.6% to $0.9398 in pre-market trading after reporting a $50 million equity purchase agreement.
    • BioNexus Gene Lab Corp. (NASDAQ:BGLC) shares gained 18.3% to $1.23 in pre-market trading after falling 15% on Thursday.
    • Faraday Future Intelligent Electric Inc. (NASDAQ:FFIE) shares rose 14.9% to $4.47 in pre-market trading. Faraday Future Intelligent Electric announced that it suspects a “coordinated effort” to undermine the company’s valuation.
    • Smith & Wesson Brands, Inc. (NASDAQ:SWBI) shares gained 11.5% to $11.72 in pre-market trading after the company reported better-than-expected financial results.
    • EBET, Inc. (NASDAQ:EBET) shares surged 10.9% to $0.0484 in pre-market trading after gaining over 5% on Thursday.
    • Appreciate Holdings, Inc. (NASDAQ:SFR) shares climbed 10.5% to $0.3004 in pre-market trading.
    • SIGNA Sports United N.V. (NYSE:SSU) rose 9.4% to $0.6599 in pre-market trading after falling over 10% on Thursday.
    • BIOLASE, Inc. (NASDAQ:BIOL) gained 9.2% to $3.45 in pre-market trading after declining 10% on Thursday.
    • Spruce Biosciences, Inc. (NASDAQ:SPRB) shares jumped 9% to $2.43 in pre-market trading.

    Losers

    • Grom Social Enterprises, Inc. (NASDAQ:GROM) fell 35.8% to $2.60 in pre-market trading. Grom Social Enterprises reported a 1-for-20 reverse stock split.
    • Digital Media Solutions, Inc. (NYSE:DMS) fell 21.2% to $3.90 in pre-market trading after jumping 36% on Thursday.
    • Kaixin Auto Holdings (NASDAQ:KXIN) fell 19.8% to $0.2723 in pre-market after surging 91% on Thursday.
    • Rosecliff Acquisition Corp I (NASDAQ:RCLF) shares fell 18.2% to $11.80 in pre-market trading after surging 40% on Thursday.
    • Inpixon (NASDAQ:INPX) shares fell 16.7% to $0.1150 in pre-market trading after declining 10% on Thursday.
    • Altisource Portfolio Solutions S.A. (NASDAQ:ASPS) fell 15.7% to $3.38 in pre-market trading after announcing a proposed public offering of common stock.
    • Soligenix, Inc. (NASDAQ:SNGX) fell 13.7% to $0.4398 in pre-market trading.
    • Versus Systems Inc. (NASDAQ:VS) shares fell 11.7% to $0.2252 in pre-market trading after declining 8% on Thursday.
    • Sigma Additive Solutions, Inc. (NASDAQ:SASI) fell 11% to $0.2402 in pre-market trading. Sigma Additive Solutions shares jumped 26% on Thursday after the company announced plans to acquire NextTrip for around $48 million and sell assets of quality assurance software to strategic buyer.
    • Panbela Therapeutics, Inc. (NASDAQ:PBLA) fell 8.5% to $1.30 in pre-market trading.

    Now Read This: Fear & Greed Index Moves To 'Neutral' Zone As Nasdaq Falls For 4th Session

    Get the next $AGBA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGBA
    $ASPS
    $BGLC
    $BIOL

    CompanyDatePrice TargetRatingAnalyst
    Spruce Biosciences Inc.
    $SPRB
    12/23/2025$283.00Outperform
    Oppenheimer
    Spruce Biosciences Inc.
    $SPRB
    12/3/2025$160.00Market Perform → Outperform
    Leerink Partners
    Spruce Biosciences Inc.
    $SPRB
    10/28/2025$254.00Mkt Perform → Mkt Outperform
    Citizens JMP
    Smith & Wesson Brands Inc.
    $SWBI
    1/27/2025$13.00Hold → Buy
    Lake Street
    Spruce Biosciences Inc.
    $SPRB
    12/11/2024Mkt Outperform → Mkt Perform
    JMP Securities
    Spruce Biosciences Inc.
    $SPRB
    12/11/2024Outperform → Perform
    Oppenheimer
    Smith & Wesson Brands Inc.
    $SWBI
    12/6/2024$18.00 → $13.00Buy → Hold
    Lake Street
    Smith & Wesson Brands Inc.
    $SWBI
    12/6/2024$18.00 → $13.00Buy → Hold
    Craig Hallum
    More analyst ratings

    $AGBA
    $ASPS
    $BGLC
    $BIOL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chair and CEO Shepro William B covered exercise/tax liability with 3,700 units of Restricted Share Units, gifted 6,300 units of Restricted Share Units and received a gift of 6,300 shares, decreasing direct ownership by 80% to 2,500 units (SEC Form 4)

    4 - ALTISOURCE PORTFOLIO SOLUTIONS S.A. (0001462418) (Issuer)

    2/27/26 8:54:07 AM ET
    $ASPS
    Other Consumer Services
    Consumer Discretionary

    Chief Legal/Compliance Officer Ritts Gregory J. covered exercise/tax liability with 5,821 shares, decreasing direct ownership by 9% to 55,911 units (SEC Form 4)

    4 - ALTISOURCE PORTFOLIO SOLUTIONS S.A. (0001462418) (Issuer)

    2/27/26 8:50:55 AM ET
    $ASPS
    Other Consumer Services
    Consumer Discretionary

    Chief Financial Officer Esterman Michelle D. covered exercise/tax liability with 4,394 shares, decreasing direct ownership by 4% to 107,322 units (SEC Form 4)

    4 - ALTISOURCE PORTFOLIO SOLUTIONS S.A. (0001462418) (Issuer)

    2/27/26 8:48:44 AM ET
    $ASPS
    Other Consumer Services
    Consumer Discretionary

    $AGBA
    $ASPS
    $BGLC
    $BIOL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Spruce Biosciences to Present at Upcoming Investor Conferences in March

    Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at two upcoming investor conferences taking place in March. Leerink Global Healthcare Conference Date and Time: March 9, 2026, at 11:20 a.m. ET Format: Fireside chat and 1x1 meetings Location: Miami, FL The Citizens Life Sciences Conference Date and Time: March 10, 2026, at 12:30 p.m. ET Format: Fireside chat and 1x1 meetings Location: Miami, FL Interested parties can access the live webcasts

    3/2/26 4:05:00 PM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lenders One Unites Members and Providers at 2026 Summit, Welcomes New President

    FORT LAUDERDALE, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- Lenders One® Cooperative ("L1" or "Lenders One"), a national mortgage cooperative of independent mortgage bankers, banks and credit unions, today announced the official launch of its 2026 Annual Summit in Fort Lauderdale. The three-day event draws a strong turnout of members and preferred providers in support of the Cooperative's continued growth and mission: helping its members improve their profitability by reducing costs, maximizing revenue, and sharing best practices. The Annual Summit serves as Lenders One's flagship event, bringing together executive leadership from across the mortgage ecosystem to connect, share insights, an

    3/2/26 9:07:20 AM ET
    $ASPS
    Other Consumer Services
    Consumer Discretionary

    Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease

    PRINCETON, N.J., Feb. 26, 2026 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) provided a positive recommendation on the Company's request for orphan drug designation for dusquetide (the active pharmaceutical ingredient in SGX945) for the treatment of Behçet's Disease, following review of the recently published Phase 2a clinical results demonstrating biological efficacy and safety in patients with Behçet's Disease.

    2/26/26 7:30:00 AM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGBA
    $ASPS
    $BGLC
    $BIOL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer initiated coverage on Spruce Biosciences with a new price target

    Oppenheimer initiated coverage of Spruce Biosciences with a rating of Outperform and set a new price target of $283.00

    12/23/25 8:47:57 AM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spruce Biosciences upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Spruce Biosciences from Market Perform to Outperform and set a new price target of $160.00

    12/3/25 8:26:32 AM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spruce Biosciences upgraded by Citizens JMP with a new price target

    Citizens JMP upgraded Spruce Biosciences from Mkt Perform to Mkt Outperform and set a new price target of $254.00

    10/28/25 8:00:24 AM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGBA
    $ASPS
    $BGLC
    $BIOL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for TRUDHESA issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug TRUDHESA (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/13/21 2:21:35 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DIHYDROERGOTAMINE MESYLATE issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug DIHYDROERGOTAMINE MESYLATE (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/7/21 1:04:43 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGBA
    $ASPS
    $BGLC
    $BIOL
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Spruce Biosciences Inc.

    SCHEDULE 13G - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)

    2/24/26 4:47:27 PM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Kaixin Holdings

    6-K - Kaixin Holdings (0001713539) (Filer)

    2/23/26 4:15:10 PM ET
    $KXIN
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    BioNexus Gene Lab Corp filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - BioNexus Gene Lab Corp (0001737523) (Filer)

    2/23/26 8:35:38 AM ET
    $BGLC
    Medical Specialities
    Health Care

    $AGBA
    $ASPS
    $BGLC
    $BIOL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Parkman Healthcare Partners Llc bought $4,585 worth of shares (256 units at $17.91) and sold $4,920 worth of shares (257 units at $19.14) (SEC Form 4)

    4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)

    10/15/25 4:32:43 PM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Parkman Healthcare Partners Llc bought $4,585 worth of shares (256 units at $17.91) and sold $4,920 worth of shares (257 units at $19.14) (SEC Form 4)

    4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)

    10/8/25 8:55:08 PM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHAIRMAN, CEO AND PRESIDENT Schaber Christopher J bought $20,000 worth of shares (15,132 units at $1.32), increasing direct ownership by 3,993% to 15,511 units (SEC Form 4)

    4 - SOLIGENIX, INC. (0000812796) (Issuer)

    10/3/25 1:18:09 PM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGBA
    $ASPS
    $BGLC
    $BIOL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Versus Systems Inc.

    SC 13G/A - Versus Systems Inc. (0001701963) (Subject)

    11/14/24 7:30:32 PM ET
    $VS
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Spruce Biosciences Inc.

    SC 13G/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)

    11/14/24 5:45:17 PM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Faraday Future Intelligent Electric Inc.

    SC 13G/A - FARADAY FUTURE INTELLIGENT ELECTRIC INC. (0001805521) (Subject)

    11/14/24 4:56:24 PM ET
    $FFIE
    Auto Manufacturing
    Consumer Discretionary

    $AGBA
    $ASPS
    $BGLC
    $BIOL
    Financials

    Live finance-specific insights

    View All

    Altisource Portfolio Solutions S.A. Schedules Fourth Quarter 2025 Conference Call

    LUXEMBOURG, Feb. 19, 2026 (GLOBE NEWSWIRE) -- On Wednesday, March 4, 2026, Altisource Portfolio Solutions S.A. ("Altisource") (NASDAQ:ASPS) will report earnings for the fourth quarter 2025. A press release and presentation will be available on Altisource's website in the Investor Relations section. Altisource will also host a conference call at 8:30 a.m. EST on the same day to discuss its fourth quarter 2025 results. A link to the live audio webcast will be available on Altisource's website in the Investor Relations section. Those who want to listen to the call should go to the website at least fifteen minutes prior to the call to register, download and install any necessary audio softwar

    2/19/26 6:06:35 PM ET
    $ASPS
    Other Consumer Services
    Consumer Discretionary

    Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration

    CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 18, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that through its wholly-owned subsidiary, it has exercised its warrant to acquire the common stock in Spruce Biosciences, Inc. (NASDAQ:SPRB) ("Spruce"). Following this transaction, Harbour BioMed holds approximately 3.8% of the total outstanding shares of Spruce and approximately 3.1% of the fully diluted shares of Spruce[1].

    1/18/26 7:02:00 PM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Altisource Announces Third Quarter 2025 Financial Results

    LUXEMBOURG, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Altisource Portfolio Solutions S.A. ("Altisource" or the "Company") (NASDAQ:ASPS), a leading provider and marketplace for the real estate and mortgage industries, today reported financial results for the third quarter 2025. "We delivered solid third quarter performance. We grew Service revenue and improved pre-and post-tax GAAP earnings, GAAP earnings per share, and cash flow from operations compared to the third quarter of last year. This is largely from our focus on growing our businesses that have tailwinds, cost discipline and lower interest expense," said Chairman and Chief Executive Officer William B. Shepro. Mr. Shepro further commente

    10/23/25 7:07:08 AM ET
    $ASPS
    Other Consumer Services
    Consumer Discretionary

    $AGBA
    $ASPS
    $BGLC
    $BIOL
    Leadership Updates

    Live Leadership Updates

    View All

    BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman

    Enhanced board oversight aligns subsidiary with disciplined capital allocation and strategic evaluation framework KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC) ("BioNexus" or the "Company"), today announced the completion of a governance restructuring of its wholly owned subsidiary, Chemrex Corporation Sdn. Bhd. ("Chemrex"). As part of this restructuring, Chemrex's board has been streamlined to two directors: Matthew L. Barsing, ChairmanAngeline Chong, Chief Financial Officer of BioNexus, Director New officers are expected to be appointed in the coming months. Chemrex remains a wholly owned private subsidiary of BioNexus and operates un

    2/23/26 8:30:00 AM ET
    $BGLC
    Medical Specialities
    Health Care

    Altisource Names Rick Seehausen President of Lenders One

    LUXEMBOURG, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Altisource Portfolio Solutions S.A. ("Altisource®" or the "Company") (NASDAQ:ASPS), a leading provider of real estate and mortgage solutions, today announced the appointment of Rick Seehausen as President of Lenders One®. In this role, Mr. Seehausen will lead the strategic direction and day-to-day operations of Altisource's Origination segment, including the delivery of Altisource's direct origination solutions through the Lenders One brand, alongside a growing ecosystem of integrated solutions. This model is designed to provide Lenders One members with a single, trusted access point to technology, services, and strategic providers that help i

    2/13/26 9:00:00 AM ET
    $ASPS
    Other Consumer Services
    Consumer Discretionary

    Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors

    Keli Walbert brings decades of commercial leadership experience and a proven track record of successful product launches in rare disease Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Keli Walbert to the Company's Board of Directors. "Keli joins the Board of Directors at a pivotal time as we prepare for a Biologics License Application for TA-ERT for the treatment of Sanfilippo Syndrome Type B (MPS IIIB)," said Michael Grey, Executive Chairman of Spruce Biosciences. "Her experience in successfully launch

    12/15/25 8:00:00 AM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care